The modulation of smad3 phosphorylation, a key event downstream of TGF-β1 signaling, further underscores the therapeutic potential of LiCl in mitigating the adverse cardiac effects associated with T2DM by inhibiting the TGF-β1 pathway. This evidence concerns the gene TGFB1 and type 2 diabetes mellitus.